Immune checkpoint inhibitors vs any first‐line chemotherapy
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in discontinuation due to adverse events Range of compared with any first‐line chemotherapy (low certainty).
1 finding from 1 review
- Immunotherapy for advanced or metastatic urothelial carcinoma 2023 · Cochrane Headline outcomes onlyRR 0.47 [0.2, 1.1]3 studies · 2046 participantsLow